ArticleFrontiers in immunology2026
Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation
Yang Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.